Last reviewed · How we verify
Azathioprine and Allopurinol
Azathioprine and Allopurinol is a Immunosuppressant and xanthine oxidase inhibitor Small molecule drug developed by Hvidovre University Hospital. It is currently in Phase 3 development for Autoimmune conditions requiring immunosuppression with concurrent hyperuricemia or gout prevention.
Azathioprine suppresses the immune system by inhibiting purine synthesis, while allopurinol reduces uric acid production by inhibiting xanthine oxidase.
Azathioprine suppresses the immune system by inhibiting purine synthesis, while allopurinol reduces uric acid production by inhibiting xanthine oxidase. Used for Autoimmune conditions requiring immunosuppression with concurrent hyperuricemia or gout prevention.
At a glance
| Generic name | Azathioprine and Allopurinol |
|---|---|
| Sponsor | Hvidovre University Hospital |
| Drug class | Immunosuppressant and xanthine oxidase inhibitor |
| Target | Purine synthesis pathway (azathioprine); xanthine oxidase (allopurinol) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Azathioprine is a prodrug that is converted to 6-mercaptopurine, which inhibits de novo purine synthesis and reduces T-cell and B-cell proliferation, providing immunosuppressive effects. Allopurinol inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine and xanthine to uric acid, thereby reducing serum uric acid levels. This combination is used to manage conditions where both immunosuppression and uric acid reduction are therapeutically beneficial.
Approved indications
- Autoimmune conditions requiring immunosuppression with concurrent hyperuricemia or gout prevention
Common side effects
- Myelosuppression
- Hepatotoxicity
- Nausea and vomiting
- Rash
- Allopurinol hypersensitivity syndrome
Key clinical trials
- Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis (PHASE3)
- Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azathioprine and Allopurinol CI brief — competitive landscape report
- Azathioprine and Allopurinol updates RSS · CI watch RSS
- Hvidovre University Hospital portfolio CI
Frequently asked questions about Azathioprine and Allopurinol
What is Azathioprine and Allopurinol?
How does Azathioprine and Allopurinol work?
What is Azathioprine and Allopurinol used for?
Who makes Azathioprine and Allopurinol?
What drug class is Azathioprine and Allopurinol in?
What development phase is Azathioprine and Allopurinol in?
What are the side effects of Azathioprine and Allopurinol?
What does Azathioprine and Allopurinol target?
Related
- Drug class: All Immunosuppressant and xanthine oxidase inhibitor drugs
- Target: All drugs targeting Purine synthesis pathway (azathioprine); xanthine oxidase (allopurinol)
- Manufacturer: Hvidovre University Hospital — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Autoimmune conditions requiring immunosuppression with concurrent hyperuricemia or gout prevention
- Compare: Azathioprine and Allopurinol vs similar drugs
- Pricing: Azathioprine and Allopurinol cost, discount & access